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Abstract
Up to 80% of people develop a cutaneous condition closely connected to their exposure to stressful life events. Psoriasis is a
chronic recurrent inflammatory skin disorder with multifactorial etiology, including genetic background, environmental
factors, and immune system disturbances with a strong cytokine component. Moreover, psoriasis is variably associated with
sleep disturbance and sleep deprivation. This study evaluated the influence of sleep loss in the context of an animal model
of psoriasis by measuring cytokine and stress-related hormone levels. Male adult Balb/C mice with or without psoriasis were
subjected to 48 h of selective paradoxical sleep deprivation (PSD). Sleep deprivation potentiated the activities of kallikrein-5
and kallikrein-7 in the skin of psoriatic groups. Also, mice with psoriasis had significant increases in specific pro-
inflammatory cytokines (IL-1b, IL-6 and IL-12) and decreases in the anti-inflammatory cytokine (IL-10) after PSD, which were
normalized after 48 h of sleep rebound. Linear regression showed that IL-2, IL-6 and IL-12 levels predicted 66% of
corticosterone levels, which were selectively increased in psoriasis mice subject to PSD. Kallikrein-5 was also correlated with
pro-inflammatory cytokines, explaining 58% of IL-6 and IL-12 variability. These data suggest that sleep deprivation plays an
important role in the exacerbation of psoriasis through modulation of the immune system in the epidermal barrier. Thus,
sleep loss should be considered a risk factor for the development of psoriasis.
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Introduction
Psoriasis is a chronic inflammatory skin disease that affects 1–
3% of the population [1]. Morphologically, psoriasis is character-
ized by epidermal hyperproliferation and neutrophil infiltrates in
the epidermis. The accumulation of neutrophils appears to be
related to the onset and maintenance of the acute phase of the
disease, leading to skin hardening and flaking. Once present in the
epidermis, the neutrophils release granules containing several
enzymes, including active human neutrophil elastase (HNE) [2].
Keratinocyte proliferation is stimulated by the presence of HNE
[3], which is found in abundance in the bottom membrane of
psoriatic lesions [4]. In addition to HNE, other enzymes such as
tryptases, metalloproteases and cathepsins B, L and D have also
been linked to the pathogenesis and maintenance of psoriasis.
These enzymes play an important role in keratinocyte proliferation
[5].
Clinically, psoriasis is shown by sharply demarcated scaly
erythematous plaques commonly found on the scalp, elbows,
and knees. The disorder is thought to result from a polygenic
predisposition [6] combined with triggering factors such as
injury to the skin, infections [7], endocrine factors, and stress
[8]. Strong evidence suggests that immune mechanisms, such as
persistent activation of T-lymphocytes, excessive proliferation of
keratinocytes, and reactivation of proto-oncogenes, may play a
role in the pathogenesis of psoriasis [9]. Additionally, recent
studies have demonstrated that cytokines can be found in the
affected psoriatic areas and contribute significantly to the
pathogenesis of the disease [10,11,12]. Moreover, the expression
of kallikreins, mainly kallikrein-5 and kallikrein-7, is increased
during the acute phase of psoriasis progression and is associated
with abnormal differentiation of keratinocytes [13]. Kallikreins
are major skin serine proteases responsible for early hydrolysis
of corneodesmosomal proteins, such as desmoglein 1, desmo-
collin 1, and corneodesmosin, which leads to desquamation
[14].
The impact of psoriasis on quality of life has been
extensively investigated [15]. Psoriasis impairs the use of
hands, walking, sitting, standing for long periods, sexual
function, and sleep [16]. Particularly, poor sleep quality
adversely affects quality of life in patients with psoriasis.
Pruritus, depression, and pain interfere with sleep duration
and structure by increasing nocturnal awakenings and leading
to sleep deprivation and fragmentation [17]. Lack of sleep itself
has important effects on immunological integrity and noctur-
nal secretion of cytokines [18,19,20,21,22,23,24] and may be
considered another risk factor for psoriasis. This bi-directional
interaction between the central nervous system and the
immune system has been focus of intense research in recent
decades [25]. In this sense, the current study aimed to
understand the role sleep loss plays in psoriasis by examining
related cytokine and hormonal profiles in an animal model.
Understanding the contribution of sleep deprivation to
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psoriasis may help to improve the daily lives and psoriasis
severity in patients by leading to novel therapeutic interven-
tions.
Materials and Methods
Animals
The study was performed using 79 male Balb/C mice (20–30 g)
from CEDEME (Centro de Desenvolvimento de Modelos
Experimentais). For the first experiment (cytokines and cortico-
sterone levels), a total of 49 animals were used [SHAM+CTRL
(n= 10), SHAM+PSD (n= 10), PSO+CTRL (n= 11), PSO+PSD
(n= 8) and PSO+SR48 (n= 10)]. For the second experiment (skin
activity of kallikrein-5 and kallikrein-7), a total of 30 mice were
used [SHAM+CTRL (n= 6), SHAM+PSD (n= 6), PSO+CTRL
(n= 6), PSO+PSD (n= 6) and PSO+SR48 (n= 6)]. The animals
were maintained under controlled conditions with a light-dark
period of 12:12 h, temperature of 2261uC, and free access to a
commercial diet (Nuvilab) and water. The animals had a 2 week
adaptation period following transfer from CEDEME, after which
they were placed in individual standard cages. All procedures used
in the present study complied with the National Institutes of
Health Guide for Care and Use of Laboratory Animals. All animal
procedures were approved by the Ethical Committee of the
Universidade Federal de Sao Paulo (#0233/08).
Experimental protocol
Animals were randomly assigned to SHAM (sham procedure) or
PSO (psoriasis induction) group. These groups were further
divided into either the control (CTRL) or paradoxical sleep
deprivation (PSD) conditions. The animals in CTRL condition
were kept undisturbed in their home cages with normal access to
sleep-wake cycle (regular 12:12 h light/dark cycle). However, the
animals in PSD condition had their sleep-wake cycle disturbed by
48 h of sleep deprivation, as further described below. Finally,
another group received PSD followed by 48 h of sleep rebound
Figure 1. Experimental protocol. Experimental timeline for each condition: SHAM+CTRL (sham procedure followed by sleep control condition,
n = 10), SHAM+PSD (sham procedure followed by 48 h of paradoxical sleep deprivation, n = 10), PSO+CTRL (psoriasis induction followed by sleep
control condition, n = 11), PSO+PSD (psoriasis induction followed by 48 h of paradoxical sleep deprivation, n = 8) and PSO+SR48 (psoriasis induction
followed by 48 h of sleep rebound, n = 10).
doi:10.1371/journal.pone.0051183.g001
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(free opportunity for sleep recovery in the home cage). Figure 1
shows the experimental design with 5 groups: SHAM+CTRL
(sham procedure in control conditions), SHAM+PSD (sham
procedure followed by 48 h of paradoxical sleep deprivation),
PSO+CTRL (psoriasis induction in control conditions), PSO+PSD
(psoriasis induction followed by 48 h of paradoxical sleep
deprivation) and PSO+SR48 (48 h of paradoxical sleep depriva-
tion followed by psoriasis induction and 48 h of sleep rebound).
We elected to not include a SHAM+SR48 group since our main
objective was to evaluate whether the changes caused by sleep
deprivation in the psoriasis model would be recovered by 48 h of
sleep rebound.
Induction of psoriasis
Psoriasis induction was induced by HNE protocol [3]. This
model was chosen since it causes a number of structural and
functional abnormalities characteristic of early psoriasis stages with
clear pathogenesis, in contrast to other models of spontaneous
mutations (asebia, chronic proliferative dermatitis, and flaky skin)
which lack clear pathogenesis [26,27,28]. Also, the concentrations
of HNE tested in the HNE model are comparable with those
found on the skin surface of psoriatic lesions [29], and it better
mimics the early stages of psoriasis as HNE is detected
predominantly in acute lesions in humans [4]. However, the
HNE model has not yet been evaluated for its contribution for the
immunopathogenesis of psoriasis. Although many other animal
models appear to be more suitable to examine the role of cytokines
because of their immunological basis (K14/IL1a, K14/IL-6,
involucrin/IFNc, H14/TGF/alpha, K10/BMP-6 models)
[30,31,32,33,34], it seems that a single cytokine alone is not
sufficient to induce the complex tissue alterations that characterize
psoriasis; it is more likely that psoriasis involves a cytokine network
[35]. Also, all of these transgenic rodent models present relatively
low penetrance of the psoriasiform phenotypes.
Briefly, on the third day of the experimental protocol (Figure 1),
all the animals were anesthetized with ketamine and xylazine
(10 mg/kg and 5 mg/kg body weight, respectively, i.p.) and had
the dorsal region trichotomized. The skin was treated with acetone
and a 1 cm2 area marked, which was then covered with an
adherent aluminum chamber (Finn Chambers on Scanpor,
Hermal, Reinbek, Germany). In animals assigned to PSO
induction, the skin beneath the chamber was then treated with a
solution of HNE 10 nM pH 7.5 (20 mL) (Merck, Brazil). The
SHAM groups received vehicle buffer Tris 50 mM pH 7.5 (20 mL)
on the skin covered by the adherent aluminum chamber. Body
weight was measured on day 1 and day 5 of the experimental
protocol.
Paradoxical sleep deprivation
Animals in the PSD condition were paradoxically sleep
deprived for 48 h using the modified multiple platform method.
To minimize the stress associated with the PSD, the animals were
adapted to this method during 3 consecutive days for a short
period of time. The PSD started before (PSO+SR48 group) and
after (SHAM+PSD and PSO+PSD groups) psoriasis induction or
sham procedure. Each mouse was individually placed inside the
cage (34618612 cm) containing 5 circular platforms (3.5 cm in
diameter) with water up to 1 cm of their upper surface. At the
onset of each paradoxical sleep episode, the animals present a loss
of muscle tonus, causing them to fall into the water and be
Figure 2. Skin illustration. Representative pictures of skin from different mice groups after the experimental protocol: SHAM+CTRL (A),
SHAM+PSD (B), PSO+CTRL (C), PSO+PSD (D) and PSO+SR48 (E).
doi:10.1371/journal.pone.0051183.g002
Figure 3. Body weight. Initial (Day 1) and final (Day 5) body weight in different groups: SHAM+CTRL (sham procedure followed by sleep control
condition, n = 10), SHAM+PSD (sham procedure followed by 48 h of paradoxical sleep deprivation, n = 10), PSO+CTRL (psoriasis induction followed by
sleep control condition, n = 11), PSO+PSD (psoriasis induction followed by 48 h of paradoxical sleep deprivation, n = 8) and PSO+SR48 (psoriasis
induction followed by 48 h of sleep rebound, n = 10). *p,0.05 compared to respective initial body weight. Values expressed as mean 6 SEM.
doi:10.1371/journal.pone.0051183.g003
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awakened. Previous experiments have shown that this method
causes a total suppression of paradoxical sleep in mice and a mild
reduction of slow wave sleep [36,37]. Food and water were
available ad libitum during PSD and the water in the cage was
changed once a day. For the CTRL condition and the sleep
rebound period of PSO+SR48, animals were kept individually in
their home cages (undisturbed sleep-wake cycle in normal bedding
with free access to water and food) in the same room as the PSD
groups. We did not include large platform controls, which is a
stress control method widely accepted in sleep research, since we
elect to control for this effect by measuring corticosterone levels.
Large platforms controls present disturbed sleep architecture that
could interfere in this study [38].
Figure 4. Circulating cytokines. Plasma concentration of cytokines A) IL-1b (pg/mL), B) IL-6 (pg/mL), C) IL-12 (pg/mL) and D) IL-10 (pg/mL) in
different groups: SHAM+CTRL (sham procedure followed by sleep control condition, n = 10), SHAM+PSD (sham procedure followed by 48 h of
paradoxical sleep deprivation, n = 10), PSO+CTRL (psoriasis induction followed by sleep control condition, n = 11), PSO+PSD (psoriasis induction
followed by 48 h of paradoxical sleep deprivation, n = 8) and PSO+SR48 (psoriasis induction followed by 48 h of sleep rebound, n = 10). *p,0.05
compared to SHAM+CTRL; #p,0.05 compared to PSO+CTRL; ¥p,0.05 compared to PSO+SR48; +p,0.05 compared to all groups. Values expressed
as mean 6 SEM.
doi:10.1371/journal.pone.0051183.g004
Table 1. Cytokines.
Group IFNc (pg/mL) IL-2 (pg/mL) TNFa (pg/mL) IL-17 (pg/mL)
SHAM+CTRL 14.761.6 90.7614.2 15.261.2 3.162.1
SHAM+PSD 15.562.0 122.8617.7 16.260.5 5.860.8
PSO+CTRL 15.062.4 85.1616.2 16.261.3 4.861.2
PSO+PSD 17.462.5 127.569.7 21.666.3 6.962.3
PSO+SR48 14.962.8 94.1615.7 20.262.3 9.265.0
Plasma concentration of cytokines IFNc (pg/mL), IL-2 (pg/mL), TNFa (pg/mL)
and IL-17 (pg/mL) in different groups: SHAM+CTRL (sham procedure followed
by sleep control condition, n = 10), SHAM+PSD (sham procedure followed by
48 h of paradoxical sleep deprivation, n = 10), PSO+CTRL (psoriasis induction
followed by sleep control condition, n = 11), PSO+PSD (psoriasis induction
followed by 48 h of paradoxical sleep deprivation, n = 8) and PSO+SR48
(psoriasis induction followed by 48 h of sleep rebound, n = 10). No statistically
significant differences. Values expressed as mean 6 SEM.
doi:10.1371/journal.pone.0051183.t001
Figure 5. Stress hormone. Plasma concentration of corticosterone
(ng/mL) in different groups: SHAM+CTRL (sham procedure followed by
sleep control condition, n = 10), SHAM+PSD (sham procedure followed
by 48 h of paradoxical sleep deprivation, n = 10), PSO+CTRL (psoriasis
induction followed by sleep control condition, n = 11), PSO+PSD
(psoriasis induction followed by 48 h of paradoxical sleep deprivation,
n = 8) and PSO+SR48 (psoriasis induction followed by 48 h of sleep
rebound, n = 10). *p,0.05 compared to SHAM+CTRL; #p,0.05
compared to PSO+CTRL; ¥p,0.05 compared to PSO+SR48; +p,0.05
compared to all groups. Values expressed as mean 6 SEM.
doi:10.1371/journal.pone.0051183.g005
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Blood samples for biochemical and hormonal evaluation
Forty-eight hours after PSD or sleep recovery, animals were
euthanized by rapid decapitation. Blood was collected in sterile
tubes containing liquid EDTA and centrifuged (4000 rpm at 4uC)
to obtain samples of plasma. Samples were stored at 280uC until
the assays. Cytokine determinations were performed on duplicate
plasma samples using the FlowMetrix System (Luminex100TM
platform), a multiplexed fluorescent bead-based immunoassay
which permits the simultaneous quantitation of multiple cytokines.
A custom 8-plex kit specific for mouse cytokines (Millipore, San
Francisco, CA, USA) was used to analyze interleukin (IL)-1b, IL-2,
IL-6, IL-10, IL-12, IL-17, interferon c (IFNc) and tumor necrosis
factor a (TNFa) in each 50-ml plasma sample. Sensitivity of the
assay was 2 pg/ml for each cytokine; all samples were run in the
same assay to avoid interassay variability. Concentrations of the
stress-related hormone, corticosterone, were assayed by a double
antibody radioimmunoassay method using a commercial kit
specific for mice (MP Biomedicals, NY, USA). The sensitivity of
the assay was 0.25 ng/ml.
Kallikrein activity
Skin samples from each experimental group were processed in
buffer (Tris 50 mM, NaCl 500 mM, Tween 20 0.005%, pH 8.0)
for the kallikrein activity assays. Kallikrein-like activity was assayed
by the use of Abz-KLRFSKQ-EDDnp (for kallikrein-5; k5) and
Abz-KLRSSKQ-EDDnp (for kallikrein-7; k7). For k5-like activity,
samples were incubated with 50.0 mM PPACK II for 10 min at
37.0uC and then 10.0 mM of the substrate was added. For k7-like
activity, samples were incubated with 50.0 mM PPACK II or
100 mM TPCK for 10 min at 37.0uC and then 10.0 mM of the
substrate was added. Control reactions were held in the absence of
the inhibitors. Hydrolysis of the substrates was measured in
l=320 nm l=420 nm in the microplate reader.
Statistical methods
All data met the assumptions of normality and homogeneity,
and so were evaluated using one-way ANOVAs followed by post-
hoc Tukey’s test, when necessary. For body weight analysis, one-
way ANOVA with repeated measures was used, followed by
Tukey’s test. To evaluate the relationship between cytokines and
corticosterone levels and cytokines and kallikrein activity, a
Pearson correlation test was performed. Cytokines that presented
a significant correlation with the dependent variable were included
in a multiple linear regression model using the stepwise way. As
the data were collected from 2 repetitions of the experimental
protocol, correlation and regression tests were performed with
data obtained from the second experiment (n = 6/group), in which
skin tissue was collected for kallikrein activity as well as blood was
collected for additional cytokine and corticosterone quantification.
The data are expressed as mean 6 SEM. The level of significance
was set at p#0.05. All analyses were performed using SPSS 17
(SPSS Inc., Chicago, IL, USA).
Results
The induction protocol reliably resulted in psoriasis by day 5
(Figure 2). Body weight was only significantly decreased across the
course of the experiment in PSO+PSD group (F(4,44) = 7.03,
p,0.05; Figure 3). In relation to the circulating cytokines levels,
ANOVA revealed differences between the groups for the following
interleukins: IL-1b (F(4,44) = 2.37, p,0.05), IL-6 (F(4,44) = 6.17,
p,0.05), IL-10 (F(4,44) = 2.32, p,0.05) and IL-12 (F(4,44) = 3.43,
p,0.05) (Figure 4). No statistical differences were observed for
IFNc, IL-2, TNFa and IL-17 (p.0.05) (Table 1). Subsequent post-
hoc tests demonstrated that IL-1a was increased in the
PSO+SR48 group compared to all other groups (p,0.05); IL-1b
showed an increase in the PSO+PSD group compared to
SHAM+CTRL (p,0.05); IL-6 was higher in the PSO+PSD
group compared to all other groups (p,0.05); and IL-12 was
significantly increased in the PSO+PSD group compared to
SHAM+CTRL, PSO+CTRL and PSO+SR48 groups (p,0.05).
Table 2. Association between cytokines and cortiscosterone.
R p
IFNc (pg/mL) 0.36 0.02
IL-1a (pg/mL) 20.08 0.62
IL-1b (pg/mL) 0.24 0.13
IL-2 (pg/mL) 0.49 0.001
IL-6 (pg/mL) 0.40 0.02
TNFa (pg/mL) 0.21 0.18
IL-10 (pg/mL) 20.16 0.36
IL-12 (pg/mL) 0.42 0.01
IL-17 (pg/mL) 0.09 0.59
Univariate analysis of factors associated with corticosterone levels (Pearson
correlation test, N = 30).
doi:10.1371/journal.pone.0051183.t002
Table 3. Corticosterone predictors.
Beta t p
(Constant) 21.33 0.20
IL-2 (pg/mL) 0.53 3.85 0.001
IL-6 (pg/mL) 0.46 3.34 0.01
IL-12 (pg/mL) 0.39 2.84 0.01
Multivariate analysis with corticosterone as the dependent variable (Multiple
linear regression, N = 30).
doi:10.1371/journal.pone.0051183.t003
Figure 6. Kallikrein-5. Skin kallikrein-5 (K5) activity (nmol.mg21.-
min21) in different groups: SHAM+CTRL (sham procedure followed by
sleep control condition, n = 6), SHAM+PSD (sham procedure followed
by 48 h of paradoxical sleep deprivation, n = 6), PSO+CTRL (psoriasis
induction followed by sleep control condition, n = 6), PSO+PSD
(psoriasis induction followed by 48 h of paradoxical sleep deprivation,
n = 6) and PSO+SR48 (psoriasis induction followed by 48 h of sleep
rebound, n = 6). *p,0.01 compared to SHAM+CTRL; #p,0.001
compared to SHAM+PSD; ¥p,0.05 compared to PSO+CTRL and
PSO+SR48. Values expressed as mean 6 SEM.
doi:10.1371/journal.pone.0051183.g006
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ANOVA revealed differences in corticosterone levels between
groups (F(4,44) = 4.43, p,0.05), with post hoc tests showing that
corticosterone was increased in the PSO+PSD group compared to
SHAM+CTRL, PSO+CTRL and PSO+SR48 groups (p,0.05)
(Figure 5). Pearson’s correlation analysis between each cytokine and
corticosterone levels revealed small positive correlations for IFNc
(R=0.36, p,0.05), IL-2 (R=0.49, p,0.001), IL-6 (R=0.40,
p,0.05) and IL-12 (R=0.42, p,0.01; Table 2). Multiple linear
regression performed with IFNc, IL-2, IL-6 and IL-12 as predictors
of corticosterone levels demonstrated that IL-2 (Beta=0.53, t=3.85,
p,0.001), IL-6 (Beta=0.46, t=3.34, p,0.01) and IL-12 (Be-
ta=0.39, t=2.84, p,0.01) entered the model (R=0.81; R2 = 0.66;
p,0.0001) (Table 3).
For the kallikrein-5 activity, ANOVA showed a group effect
(F(4,25) = 19.59, p,0.0001) with increased activity in PSO+CTRL,
PSO+PSD and PSO+SR48 groups compared to SHAM+CTRL
(p,0.01) (Figure 6). Moreover, PSO+PSD group had increased
kallikrein-5 activity compared with SHAM+PSD, PSO+CTRL and
PSO+SR48 groups (p,0.01). Similarly, kallikrein-7 activity had
differences between the groups (F(4,25) = 33.05, p,0.0001), show-
ing increased activity in PSO+CTRL, PSO+PSD and PSO+SR48
compared to SHAM+CTRL and SHAM+PSD groups (p,0.001)
(Figure 7). PSO+PSD potentiated the increase in kallikrein-7
activity in relation to PSO+CTRL and PSO+SR48 groups
(p,0.05). Pearson’s correlation analysis between cytokines, cortico-
sterone and kallikrein-5 showed a significant association between
kallikrein-5 activity and the variables IL-6 (R=0.59, p,0.01), IL-12
(R=0.50, p,0.01), IL-17 (R=0.52, p,0.01), and corticosterone
(R=0.47, p,0.05) (Table 4). In relation to kallikrein-7, the
correlation was significant only for IL-12 (R=0.46, p,0.01)
(Table 4). Multiple linear regression performed with IL-6, IL-12,
IL-17 and corticosterone as predictors of kallikrein-5 activity
demonstrated that only the pro-inflammatory cytokines IL-6
(Beta=0.59, t=3.94, p,0.001) and IL-12 (Beta=0.46, t=3.08,
p,0.01) entered the model (R=0.76; R2 = 0.58; p,0.0001)
(Table 5).
Discussion
The current study examined the effects of sleep deprivation on
plasma cytokines in an experimental model of psoriasis. As
expected, all psoriatic animals had increases in kallikrein-5 and
kallikrein-7 activity, which were potentiated by sleep deprivation,
and attenuated by 48 h of sleep rebound. Also, pro-inflammatory
cytokines (IL-1b, IL-6 and IL-12) were significantly increased
solely in the PSO+PSD group, and were restored to normal levels
after 48 h of sleep rebound. However, a sleep deprivation-
dependent decrease in the anti-inflammatory cytokine (IL-10) was
observed in both SHAM+PSD and PSO+PSD, suggesting sleep
deprivation may be an important risk condition for psoriasis [39].
In addition, a multiple linear regression model revealed an
association between the activity of the kallikreins and pro-
inflammatory cytokines, especially IL-6 and IL-12, which signif-
icantly predicted kallikrein-5 activity. The same pattern was
observed in corticosterone concentrations, which were elevated
only in psoriasis mice subjected to PSD. These changes were also
directly correlated to the immune response and to skin kallikrein
activity in psoriasis mice. Together, the results suggest a
relationship between hypothalamus-pituitary-adrenal (HPA) axis
activation and pro-inflammatory/anti-inflammatory cytokine im-
balance in psoriasis animals challenged with sleep deprivation.
Figure 7. Kallikrein-7. Skin kallikrein-7 (K7) activity (nmol.mg21.min21) in different groups: SHAM+CTRL (sham procedure followed by sleep control
condition, n = 6), SHAM+PSD (sham procedure followed by 48 h of paradoxical sleep deprivation, n = 6), PSO+CTRL (psoriasis induction followed by
sleep control condition, n = 6), PSO+PSD (psoriasis induction followed by 48 h of paradoxical sleep deprivation, n = 6) and PSO+SR48 (psoriasis
induction followed by 48 h of sleep rebound, n = 6). *p,0.01 compared to SHAM+CTRL; #p,0.001 compared to SHAM+PSD; ¥p,0.05 compared to
PSO+CTRL and PSO+SR48. Values expressed as mean 6 SEM.
doi:10.1371/journal.pone.0051183.g007
Table 4. Association between kallikreins, cytokines and corticosterone.
IFNc IL-1b IL-2 TNFa IL-12 IL-6 IL-10 IL17 Corticosterone
Kallikrein-5 R 0.22 0.35 0.17 0.33 0.50 0.59 0.14 0.52 0.47
p 0.22 0.06 0.37 0.08 0.01 0.01 0.51 0.01 0.02
Kallikrein-7 R 0.04 0.17 0.08 0.31 0.46 0.34 0.05 0.30 0.37
p 0.82 0.38 0.69 0.10 0.01 0.10 0.80 0.14 0.07
Univariate analysis of factors associated with kallikrein-5 and kallikrein-7 activities (Pearson correlation test, N = 30).
doi:10.1371/journal.pone.0051183.t004
Sleep, Psoriasis and the Immune System
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Stress is a relevant factor in triggering psoriasis symptomatology
[40,41] and is intrinsically related to sleep deprivation through
HPA activation [42,43,44]. Evidence suggests that the efficacy of
corticosterone-mediated feedback determines the characteristics of
basal and stress-related activity [45]. Importantly, the current
study found a positive correlation between corticosterone and pro-
inflammatory cytokines, which were significantly increased in the
PSO+PSD group. Remarkably, the increase in IL-2, L-6, and IL-
12 were responsible for at least 66% of the changes observed in
corticosterone levels. This result indicates that PSD is associated
with changes in immune function which are known to be involved
in psoriasis. This may be one potential explanation of how stress
triggers psoriatic eruption.
Our results also demonstrate a cause-effect relationship between
the immune response and kallikrein-5 activity, showing that the
pro-inflammatory cytokines IL-2 and IL-12 explain 58% of the
changes observed in kallikrein-5 activity. These data suggest that
sleep deprivation may change the cytokine environment leading to
excessive protease activity, which in turn affects the epidermal
barrier and contributes to psoriasis pathogenesis. However, this
may not be directly dependent on the HPA axis activation, since
corticosterone was not a predictor of kallikrein-5 activity, but only
associated with it. On the other hand, Morizane et al. [46] showed
no changes in kallikrein-5 expression of normal human epidermal
keratinocytes stimulated with type-2 cytokines (IL-4 and IL-13).
Although this was an in vitro study, the authors found that only
type-2 cytokines were able to increase kallikrein-7 expression and
function in an atopic dermatitis model [46].
Our data also demonstrated that the PSD and psoriasis
induction themselves were not enough to cause an HPA stress-
related response or to change the circulating cytokines profile,
although the combination of the PSD and psoriasis presented
synergistic effects. However, the PSO+SR48 group showed that
the reestablishment of sleep homeostasis was essential to restore
the balance between pro-inflammatory/anti-inflammatory cyto-
kines and corticosterone levels. In patients, it is difficult to isolate
the stress related to lifestyle from the pathophysiology of the
disease; these results could explain at least in part the contradiction
found between the neuroendocrine profile of the HPA axis and
cytokines in psoriatic patients [47,48], i.e., the level of cytokines
could change given a certain level of cortisol in psoriasis patients.
However, in contrast to previous studies [49,50] we did not find
increased levels of type-1 cytokines such as IFNc, TNFa, IL-6 and
IL-12 or decreases in type-2 cytokines like IL-10 [12,51] in PSO
mice that were not sleep deprived. Only mice in the PSO+PSD
developed significant alterations in the cytokine network. This may
be explained by the short period established for the duration of the
psoriasis model. But, despite the short induction of psoriasis, the
PSD challenge was still able to induce inflammatory markers,
which suggests that the effects of PSD can be severe.
Cytokine imbalance represents an interesting target in psoriasis.
Overexpression of IL-6 and IL-12 has been implicated in the
pathology of psoriasis in addition to several other autoimmune and
chronic inflammatory diseases [11,52,53,54]. IL-6 induces an
acute inflammatory reaction and supports the activation of
lymphocytes, myeloid cells and keratinocytes in the epidermis,
which may increase the serum level of IL-6, leading to increased
inflammation. Relative deficiency of IL-10 is also seen in psoriatic
patients and may be important in the development of this disease
[55,56,57]. However, no significant differences were found in the
polymorphisms of IL-6 and IL-10 promoter genes between
patients with psoriasis and healthy controls [58]. Of note, PSD
has been demonstrated to increase type-1 cytokines IL-1b, IL-6
and IL-12 levels in rats in a sleep loss-dependent manner [59,60].
Since our results show that these cytokines can modulate the
kallikrein-5 function, it is important to highlight the importance of
good sleep quality for maintenance of skin integrity.
It is important to note that the main cytokine alterations were
observed only with the combination of both sleep deprivation and
psoriasis. This may be due to the animal model chosen for this
study. Another animal model based on T-cell transfers to
pathogen-free scid/scid mice (CD4+/CD45RBhi model) presents
an inflammatory cytokine response via dysregulated T-cells with
altered keratinocyte differentiation, mimicking human psoriasis
[61]. It takes, however, around 8 weeks to be completely
established in all subjects and also causes intestinal inflammation
in addition to the skin inflammation [62,63]. As our main goal was
to evaluate the effects of the interaction between sleep deprivation
and early stages of psoriasis on cytokines levels, we chose the HNE
model due to concerns that possible cytokine changes could be
masked in the CD4+/CD45RBhi model due to high baseline
cytokine levels. However, additional studies in this model should
be performed to expand upon and generalize our results. Clearly,
there is no perfect model for psoriasis. Each one is based on a
different mechanism with its similarities to psoriasis as well as its
limitations.
Circadian variations have been found in cytokines levels
[64,65,66]. Many facets of inflammation such as pro-inflammatory
cytokines present circadian pattern in humans, typically peaking
during the night [67]. People suffering from rheumatoid arthritis
exhibit diurnal variation in disease severity associated with
fluctuations in IL-6 levels [68]. Also, significant temporal
dependence of LPS-induced shock is reported in mice [67,69]
and this response is potentiated by circadian disruption mimicking
jet lag [70]. Increasing evidence also shows that the circadian
rhythm, in comparison to sleep deprivation, favors the production
of type-1 cytokines [71]. Immune factors such as cytokines can also
influence the phase of the circadian clock, providing a bidirec-
tional flow of circadian information in the immune system. For
example, the circadian clock protein Per 2 has been shown to
control the expression of the pattern recognition receptor TLR9,
and this regulation translates to daily variations in TLR9
responsiveness modulated by cytokine response [72]. Although
important, it is ultimately difficult to dissect the influence of sleep
from the biological clock. The marked sleep-wake rhythm is
controlled by both the circadian system and sleep, but also by
confounding influences like body posture, physical activity, feeding
and fasting, lighting, and ambient temperature [73]. Thus,
considering the interference of the circadian rhythm may be
difficult in the current study. Since the effect of circadian rhythm
vs. sleep deprivation clearly depends on the time of the assessment,
a single blood draw cannot provide conclusive data. Some
evidence shows that psoriatic patients present disturbed circadian
rhythms due to a loss of the nocturnal peak in melatonin secretion
Table 5. Kallikrein-5 predictors.
Beta t p
(Constant) 6.17 0.0001
IL-6 (pg/mL) 0.59 3.94 0.001
IL-12 (pg/mL) 0.46 3.08 0.006
Multivariate analysis with kallikrein-5 as the dependent variable (Multiple linear
regression, N = 30).
doi:10.1371/journal.pone.0051183.t005
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[74]. In addition, psoriasis patients show desynchronized circadian
acrophases compared to control subjects in many other variables
such as oral temperature, arterial blood pressure, pulse, and
electrolytes [75]. Taken together, these data suggest that
additional studies on the circadian rhythm should also be
considered for a better understanding of the interactions between
sleep deprivation and cytokines in the development of psoriasis.
This is the first study to investigate the involvement of sleep
deprivation in the inflammatory and stress-related response of an
animal model of psoriasis. Our results add supporting evidence to
novel therapeutic options (such as anti-interleukins treatments and
sleep quality care with polysomnography monitoring) as well as a
better understanding of the role of sleep in the pathophysiology of
inflammatory skin diseases such as psoriasis. Moreover, the
positive correlation of a stress-related hormone with circulating
type-1 cytokines and kallikrein activity suggested that altered HPA
activity can be a consequence of the immune response associated
with the interaction between psoriasis and sleep deprivation.
Future studies should examine longer durations for the psoriasis
model as well as histological skin analysis that could be correlated
with the systemic cytokine response. Also, sleep recordings would
be important to characterize the sleep pattern in this psoriasis
model in order to verify the distribution of sleep stages and their
relationship with the cytokine profile. Although in humans, acute
sleep deprivation and chronic sleep restriction are more commonly
observed than PSD, the relevance of this method to the human
condition is addressed in the mechanisms it can clearly provide,
showing the importance of a specific sleep stage (paradoxical sleep
or REM) in the context of psoriasis. In conclusion, our data
suggest that sleep plays an important role in the exacerbation of
psoriasis via modulation of the immune system, and that sleep loss
should be considered a risk factor for the initiation, development,
and recurrence of psoriasis.
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